OpenURL Connection Search

Select item for more details and to access through your institution.

Peripheral blood stem cell transplantation for POEMS syndrome.
Published in:
Bone Marrow Transplantation, 2002, v. 30, n. 6, p. 401, doi. 10.1038/sj.bmt.1703670
By:
- Peggs, K.S.;
- Paneesha, S.;
- Kottaridis, P.N.;
- Chakraverty, R.K.;
- Tobias, G.;
- Reilly, M.;
- Mahendra, P.;
- Yong, K.
Publication type:
Article
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
Published in:
Blood Cancer Journal, 2021, v. 11, n. 7, p. 1, doi. 10.1038/s41408-021-00528-x
By:
- Parry, H.;
- McIlroy, G.;
- Bruton, R.;
- Ali, M.;
- Stephens, C.;
- Damery, S.;
- Otter, A.;
- McSkeane, T.;
- Rolfe, H.;
- Faustini, S.;
- Wall, N.;
- Hillmen, P.;
- Pratt, G.;
- Paneesha, S.;
- Zuo, J.;
- Richter, A.;
- Moss, P.
Publication type:
Article
CAR T treatment access and outcomes in patients with large B‐cell lymphoma according to ethnicity and socioeconomic deprivation.
Published in:
Hematological Oncology, 2023, v. 41, p. 452, doi. 10.1002/hon.3164_333
By:
- Dragoi, D.;
- Cusworth, S.;
- Amrith, M.;
- Sanderson, R.;
- Paneesha, S.;
- Patten, P.;
- Potter, V.;
- Hardefeldt, P.;
- Yallop, D.;
- Chaganti, S.;
- Burns, D.;
- Kuhnl, A.
Publication type:
Article
INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.175_2880
By:
- Hübel, K.;
- Scholz, C. W.;
- Luminari, S.;
- Salar, A.;
- Wahlin, B. E.;
- Gopal, A. K.;
- Bonnet, C.;
- Trneny, M.;
- Paneesha, S.;
- Manzke, O.;
- Seguy, F.;
- Li, D.;
- Sehn, L. H.
Publication type:
Article
NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 67, doi. 10.1002/hon.35_2629
By:
- Pettitt, A.R.;
- Barrington, S.;
- Kalakonda, N.;
- Khan, U.T.;
- Jackson, R.;
- Carruthers, S.;
- Oates, M.;
- Lin, K.;
- Ardeshna, K.;
- Eyre, T.;
- Fox, C.P.;
- Kennedy, B.;
- Linton, K.;
- Malladi, R.;
- Menne, T.;
- Okosun, J.;
- Paneesha, S.;
- Rule, S.;
- Johnston, A.;
- Trotman, J.
Publication type:
Article
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 217, doi. 10.1002/hon.32_2630
By:
- Pettitt, A.;
- Kalakonda, N.;
- Cicconi, S.;
- Murphy, C.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.;
- Knechtli, C.;
- Hamblin, M.
Publication type:
Article
NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 67, doi. 10.1002/hon.35_2629
By:
- Pettitt, A.R.;
- Barrington, S.;
- Kalakonda, N.;
- Khan, U.T.;
- Jackson, R.;
- Carruthers, S.;
- Oates, M.;
- Lin, K.;
- Ardeshna, K.;
- Eyre, T.;
- Fox, C.P.;
- Kennedy, B.;
- Linton, K.;
- Malladi, R.;
- Menne, T.;
- Okosun, J.;
- Paneesha, S.;
- Rule, S.;
- Johnston, A.;
- Trotman, J.
Publication type:
Article
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 217, doi. 10.1002/hon.32_2630
By:
- Pettitt, A.;
- Kalakonda, N.;
- Cicconi, S.;
- Murphy, C.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.;
- Knechtli, C.;
- Hamblin, M.
Publication type:
Article
EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 88, doi. 10.1002/hon.2437_77
By:
- Pettitt, A.R.;
- Kalakonda, N.;
- Polydoros, F.;
- Bickerstaff, M.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Jenner, M.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.P.;
- Knechtli, C.
Publication type:
Article
Treatment outcomes using involved field and involved site radiotherapy for NHL and HL: Retrospective analysis from a large UK Radiotherapy centre.
Published in:
Hematological Oncology, 2017, v. 35, p. 333, doi. 10.1002/hon.2439_77
By:
- Jayalathike, D.M.;
- Stevens, A.;
- Paneesha, S.;
- Chaganti, S.;
- Hassan, Y.;
- Zarkar, A.M.
Publication type:
Article
HighD-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes.
Published in:
British Journal of Haematology, 2006, v. 135, n. 1, p. 85, doi. 10.1111/j.1365-2141.2006.06260.x
By:
- Paneesha, S.;
- Cheyne, E.;
- French, K.;
- Bacchu, S.;
- Borg, A.;
- Rose, P.
Publication type:
Article
Stem cell transplantation for chronic lymphocytic leukaemia.
Published in:
British Journal of Haematology, 2005, v. 128, n. 2, p. 145, doi. 10.1111/j.1365-2141.2004.05250.x
By:
- Paneesha, S.;
- Milligan, D. W.
Publication type:
Article

Found: 12